JCIA
DNLI icon

Jackson Creek Investment Advisors’s Denali Therapeutics DNLI Stock Holding History

Jackson Creek Investment Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,381
Closed -$840K – 316
2022
Q3 		$840K Buy
+27,381
New +$890K 0.39% 108

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Jackson Creek Investment Advisors's DNLI Position: Q4 2022 in Review

Jackson Creek Investment Advisors sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 27,381 shares — an estimated $840K sold.

Jackson Creek Investment Advisors first reported a position in DNLI in Q3 2022 and held it in 1 quarter. The position peaked at $840K in Q3 2022. 199 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Jackson Creek Investment Advisors reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 27,381 Denali Therapeutics shares in Q4 2022, an estimated $840K.
  • Jackson Creek Investment Advisors first reported a position in Denali Therapeutics in Q3 2022 and held it in 1 quarter.
  • Jackson Creek Investment Advisors's Denali Therapeutics position peaked at $840K in Q3 2022.
  • 199 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.